Literature DB >> 26064311

Peroxisome proliferator-activated receptor-γ (PPARγ) Pro12Ala polymorphism and colorectal cancer (CRC) risk.

Wei Wang1, Yan Shao2, Shenhua Tang1, Xianyong Cheng1, Haifeng Lian1, Chengyong Qin3.   

Abstract

BACKGROUND: The association between the peroxisome proliferator-activated receptor-γ (PPARγ) Pro12Ala polymorphism and colorectal cancer (CRC) risk was inconclusive. We conducted a meta-analysis to evaluate the association between PPARγ Pro12Ala polymorphism and CRC risk. MATERIAL AND
METHOD: We searched Pubmed, EMBASE, and China National Knowledge Infrastructure databases. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated.
RESULTS: A total of 17 case-control studies with 12635 and 15803 controls were included in this meta-analysis. Overall, PPARγ Pro12Ala polymorphism was associated with CRC risk (OR = 0.84, 95% CI 0.75-0.94, P = 0.003, I(2) = 35%). In the subgroup analysis by ethnicity, a significant association was found among Caucasians (OR = 0.85, 95% CI 0.75-0.96, P = 0.007, I(2) = 38%) but not among Asians (OR = 0.76, 95% CI 0.51-1.12, P = 0.17, I(2) = 28%). In the subgroup analysis by CRC site, a significant association was found among colon cancer (OR = 0.81, 95% CI 0.66-0.98, P = 0.03, I(2) = 16%) but not among rectal cancer (OR = 0.83, 95% CI 0.57-1.21, P = 0.34, I(2) = 63%). The sensitivity analysis did not influence the result by omitting low-quality studies (OR = 0.76, 95% CI 0.63-0.93, P = 0.006, I(2) = 51%).
CONCLUSIONS: In conclusion, this meta-analysis suggested that PPARγ Pro12Ala polymorphism was significant associated with CRC risk.

Entities:  

Keywords:  Colorectal cancer; meta-analysis; peroxisome proliferator-activated receptor; polymorphism

Year:  2015        PMID: 26064311      PMCID: PMC4443145     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  30 in total

Review 1.  Background review paper on total fat, fatty acid intake and cancers.

Authors:  Mariette Gerber
Journal:  Ann Nutr Metab       Date:  2009-09-15       Impact factor: 3.374

2.  Inflammation-related gene polymorphisms and colorectal adenoma.

Authors:  Marc J Gunter; Federico Canzian; Stefano Landi; Stephen J Chanock; Rashmi Sinha; Nathaniel Rothman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

3.  No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.

Authors:  Louise E McGreavey; Faye Turner; Gillian Smith; Katherine Boylan; D Timothy Bishop; David Forman; C Roland Wolf; Jennifer H Barrett
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

4.  Activators of the nuclear receptor PPARgamma enhance colon polyp formation.

Authors:  E Saez; P Tontonoz; M C Nelson; J G Alvarez; U T Ming; S M Baird; V A Thomazy; R M Evans
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

5.  The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas.

Authors:  Zhihong Gong; Dawen Xie; Zonglin Deng; Roberd M Bostick; Stephanie J Muga; Thomas G Hurley; James R Hebert
Journal:  Carcinogenesis       Date:  2004-11-25       Impact factor: 4.944

6.  Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.

Authors:  T Tanaka; H Kohno; S Yoshitani; S Takashima; A Okumura; A Murakami; M Hosokawa
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

7.  Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways.

Authors:  Martha L Slattery; Roger K Wolff; Karen Curtin; Frank Fitzpatrick; Jennifer Herrick; John D Potter; Bette J Caan; Wade S Samowitz
Journal:  Mutat Res       Date:  2008-10-15       Impact factor: 2.433

8.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

9.  Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition.

Authors:  Fränzel J B van Duijnhoven; H Bas Bueno-De-Mesquita; Pietro Ferrari; Mazda Jenab; Hendriek C Boshuizen; Martine M Ros; Corinne Casagrande; Anne Tjønneland; Anja Olsen; Kim Overvad; Ole Thorlacius-Ussing; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Sophie Morois; Rudolf Kaaks; Jakob Linseisen; Heiner Boeing; Ute Nöthlings; Antonia Trichopoulou; Dimitrios Trichopoulos; Gesthimani Misirli; Domenico Palli; Sabina Sieri; Salvatore Panico; Rosario Tumino; Paolo Vineis; Petra Hm Peeters; Carla H van Gils; Marga C Ocké; Eiliv Lund; Dagrun Engeset; Guri Skeie; Laudina Rodríguez Suárez; Carlos A González; María-José Sánchez; Miren Dorronsoro; Carmen Navarro; Aurelio Barricarte; Göran Berglund; Jonas Manjer; Göran Hallmans; Richard Palmqvist; Sheila A Bingham; Kay-Tee Khaw; Timothy J Key; Naomi E Allen; Paolo Boffetta; Nadia Slimani; Sabina Rinaldi; Valentina Gallo; Teresa Norat; Elio Riboli
Journal:  Am J Clin Nutr       Date:  2009-04-01       Impact factor: 7.045

10.  Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer.

Authors:  Ulla Vogel; Jane Christensen; Marianne Dybdahl; Søren Friis; Rikke D Hansen; Håkan Wallin; Bjørn A Nexø; Ole Raaschou-Nielsen; Paal S Andersen; Kim Overvad; Anne Tjønneland
Journal:  Mutat Res       Date:  2007-04-27       Impact factor: 2.433

View more
  7 in total

1.  PPARG c.1347C>T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis.

Authors:  Hao Ding; Yuanmei Chen; Hao Qiu; Chao Liu; Yafeng Wang; Mingqiang Kang; Weifeng Tang
Journal:  Oncotarget       Date:  2017-09-15

2.  Relationship of PPARG, PPARGC1A, and PPARGC1B polymorphisms with susceptibility to hepatocellular carcinoma in an eastern Chinese Han population.

Authors:  Sheng Zhang; Jiakai Jiang; Zhan Chen; Yafeng Wang; Weifeng Tang; Yu Chen; Longgen Liu
Journal:  Onco Targets Ther       Date:  2018-08-08       Impact factor: 4.147

3.  Leptin rs2167270 G > A (G19A) polymorphism may decrease the risk of cancer: A case-control study and meta-analysis involving 19 989 subjects.

Authors:  Jing Yang; Zhihui Zhong; Weifeng Tang; Jianping Chen
Journal:  J Cell Biochem       Date:  2019-01-29       Impact factor: 4.429

4.  Diet and PPARG2 Pro12Ala Polymorphism Interactions in Relation to Cancer Risk: A Systematic Review.

Authors:  Lieu Tran; Gerd Bobe; Gayatri Arani; Yang Zhang; Zhenzhen Zhang; Jackilen Shannon; Yumie Takata
Journal:  Nutrients       Date:  2021-01-18       Impact factor: 5.717

5.  Association of PPARG rs 1801282 C>G polymorphism with risk of colorectal cancer: from a case-control study to a meta-analysis.

Authors:  Jiakai Jiang; Zhiqiang Xie; JunYing Guo; Yafeng Wang; Chao Liu; Sheng Zhang; Weifeng Tang; Yu Chen
Journal:  Oncotarget       Date:  2017-08-10

Review 6.  Vascular endothelial growth factor A polymorphisms are associated with increased risk of coronary heart disease: a meta-analysis.

Authors:  Yafeng Wang; Qiuyu Huang; Jianchao Liu; Yanan Wang; Gongfeng Zheng; Ling Lin; Hui Yu; Weifeng Tang; Ziyang Huang
Journal:  Oncotarget       Date:  2017-05-02

7.  Liquiritigenin Inhibits Colorectal Cancer Proliferation, Invasion, and Epithelial-to-Mesenchymal Transition by Decreasing Expression of Runt-Related Transcription Factor 2.

Authors:  Fan-Chun Meng; Jun-Kai Lin
Journal:  Oncol Res       Date:  2018-02-22       Impact factor: 5.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.